Results 31 to 40 of about 11,087,757 (202)
Relook at DPP-4 inhibitors in the era of SGLT-2 inhibitors
World Journal of Diabetes, 2022 SGLT-2 inhibitors (SGLT-2Is) have significantly improved cardio-renal outcomes and are preferred agents in people with cardiovascular diseases, heart failure, and diabetic kidney disease. Similarly, GLP-1 receptor agonists (GLP-1RAs) have significantly improved atherosclerotic cardiovascular outcomes. To this end, DPP-4 inhibitors (DPP-4Is) are cardiac-
Singh, Awadhesh Kumar, Singh, Ritu
openaire +2 more sources
Journal of Diabetes Research, 2017 Dipeptidyl peptidase-4 (DPP-4) inhibitors are often used all over the world and exert various beneficial effects including glucose-lowering effect in many subjects with type 2 diabetes.
Masashi Shimoda +12 more
doaj +1 more source
Dipeptidyl-peptidase-4 (DPP-4) inhibitor ameliorates 5-flurouracil induced intestinal mucositis
BMC Cancer, 2019 Background Chemotherapy-induced alimentary mucositis (AM) is difficult to prevent and treatment is rarely effective. Recent study have been showed that glucagon-like peptide (GLP)-1 and GLP-2 has protective in chemotherapy-induced AM.
Jung Min Lee +12 more
doaj +1 more source
ING4 (inhibitor of growth family, member 4) [PDF]
, 2011 Review on ING4 (inhibitor of growth family, member 4), with data on DNA, on the protein encoded, and where the gene is ...
Miranda, C, Greco, A
core +1 more source
Gemigliptin: An Update of Its Clinical Use in the Management of Type 2 Diabetes Mellitus [PDF]
Diabetes & Metabolism Journal, 2016 Dipeptidyl peptidase-4 (DPP-4) inhibitors are a new class of oral antidiabetic agent for the treatment of type 2 diabetes mellitus. They increase endogenous levels of incretin hormones, which stimulate glucose-dependent insulin secretion, decrease ...
Sung-Ho Kim +3 more
doaj +1 more source
DPP-4 inhibitors subgroup analysis.
, 2019 DPP-4 inhibitors subgroup analysis.
Li-Jiuan Shen (1447438) +4 more
core +1 more source
DPP-4 inhibitor therapy and bone fractures in people with Type 2 diabetes - A systematic review and meta-analysis. [PDF]
, 2016 AIM: Fracture risk is higher in older adults with Type 2 diabetes mellitus (T2DM). Oral glucose-lowering medications have different effects on bone metabolism. The purpose of this study is to appraise the evidence from literature and determine the effect
Marlin, Carol +4 more
core +1 more source
Sitagliptin: the world’s first DPP-4 inhibitor
Медицинский совет, 2019 The prevalence of T2D is steadily increasing annually, which resulted in an active search for a way to control the disease. The last decade has seen a rise in the number of new groups of glucose-lowering drugs, which not only proved effective in the ...
N. A. Petunina +4 more
doaj +1 more source
Trends in Adverse Event Reports of Dipeptidyl Peptidase-4 Inhibitor-Associated Pemphigoid in Japan
Drugs - Real World OutcomesBackground Dipeptidyl peptidase-4 (DPP-4) inhibitors are widely used as a first-line therapy for type 2 diabetes in Japan. Precautions of the package inserts for ethical drugs containing DPP-4 inhibitors were revised for pemphigoid between 2016 and 2018.
Akina Takami +4 more
doaj +1 more source
Late Onset Dipeptidyl Peptidase -4 Inhibitor Associated Seronegative Rheumatoid Arthritis
Journal of Nepal Health Research Council, 2021 Drug-induced arthritis is not an uncommon scenario. DPP-4 inhibitors could potentially cause adverse-events mediated by cytokine-induced inflammation leading to arthritis. The activity of the DPP-4 enzyme could be inversely related to the development of
Binit Vaidya +3 more
doaj +1 more source